글로벌 근종절제술 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

근종절제술 시장 분석

이 시장은 생식 연령의 여성 사이에서 자궁 근종 의 유병률이 증가 하고 최소 침습 수술 옵션에 대한 인식이 높아짐에 따라 주도되고 있습니다. 최근의 발전에는 로봇 보조 수술 기술의 발전과 정밀도를 높이고 회복 시간을 단축하며 합병증을 최소화하는 개선된 복강경 수술 도구가 포함됩니다 . 또한 초음파 및 MRI와 같은 영상 기술의 혁신은 더 나은 진단 및 치료 계획에 도움이 됩니다. 자궁근종 절제술 시장은 또한 덜 침습적인 시술에 대한 환자 옹호가 증가하고 여성 건강에 중점을 두어 효과적인 치료 옵션에 대한 수요가 증가함에 따라 지원됩니다. 전반적으로 자궁근종 절제술 시장은 의료 서비스 제공자가 자궁근종을 관리하는 데 환자 중심적 접근 방식을 계속 우선시함에 따라 성장할 준비가 되었습니다.

근종절제술 시장 규모

글로벌 자궁근종절제술 시장 규모는 2023년에 7억 5,852만 달러로 평가되었으며, 2031년까지 1,475.17만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 8.67%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

근종절제술 시장 동향

“ 로봇 보조 수술 및 복강경 수술 방법의 혁신”

근종절제술 시장은 수술 기술의 발전과 최소 침습적 시술에 대한 환자 수요 증가로 인해 상당한 추세를 경험하고 있습니다. 로봇 보조 수술과 복강경 수술의 혁신은 자궁 근종을 치료하는 방법을 변화시키고 있으며, 향상된 정밀도와 빠른 회복 시간을 제공합니다. 주목할 만한 추세 중 하나는 외래 시술의 인기 증가로, 환자가 근종절제술을 받고 같은 날 집으로 돌아갈 수 있어 입원과 관련 비용을 최소화할 수 있습니다. 외래 진료로의 이러한 전환은 높은 수준의 치료 기준을 유지하면서 환자 경험을 개선하려는 의료 산업의 광범위한 움직임을 반영합니다. 이러한 옵션에 대한 인식이 높아짐에 따라 근종절제술 시장은 확대되어 자궁 근종을 관리하기 위한 효과적이고 덜 침습적인 솔루션을 강조할 것입니다.

보고서 범위 및 자궁근종절제술 시장 세분화         

근종절제술 시장 정의

근종 절제술은 자궁을 보존하면서 자궁 근종(근종)을 제거하기 위해 시행하는 외과적 시술입니다. 일반적으로 생식 능력을 유지하거나 자궁 절제술을 피하고자 하는 여성에게 권장됩니다. 이 시술은 근종의 크기, 위치 및 수에 따라 복부, 복강경 또는 자궁경 기술을 포함한 다양한 접근 방식을 통해 시행할 수 있습니다. 근종 절제술은 과다한 월경 출혈, 골반 통증 및 주변 장기에 가해지는 압박과 같은 근종과 관련된 증상을 완화하여 환자의 삶의 질을 개선하는 것을 목표로 합니다.

근종절제술 시장 동향

운전자

• 자궁근종의 유병률 증가

The rising prevalence of uterine fibroids among women of reproductive age serves as a significant market driver for myomectomy procedures. Fibroids are common benign tumors that can cause a range of symptoms, including heavy menstrual bleeding, pelvic pain, and pressure on surrounding organs. As awareness of these conditions increases, more women are seeking effective treatment options to alleviate their symptoms while preserving fertility. This growing demand for targeted interventions, such as myomectomy, is leading healthcare providers to prioritize these procedures, ultimately driving market growth. Addressing the needs of this patient population is crucial for enhancing quality of life and reproductive health.

•  Desire for Fertility Preservation

Many women choose myomectomy as a surgical option to remove uterine fibroids while preserving their uterus for potential future pregnancies. This desire for fertility preservation is a crucial factor influencing the demand for myomectomy procedures. Uterine fibroids can lead to complications during pregnancy and childbirth, prompting women to seek effective solutions that allow them to manage their symptoms without sacrificing their reproductive capabilities. As more women become aware of the benefits of myomectomy, including the ability to alleviate discomfort and retain fertility, healthcare providers are witnessing an increased interest in this procedure. This growing inclination significantly contributes to the expansion of the myomectomy market.

Opportunities

• Innovation in Minimally Invasive Surgical Techniques

Continuous innovation in minimally invasive surgical techniques, including robotic-assisted surgery and advanced laparoscopic methods, presents significant opportunities in the myomectomy market. These technologies enhance surgical precision, reduce recovery times, and minimize postoperative discomfort, making the procedures more appealing to patients. As patients increasingly prefer less invasive options that promote quicker healing and fewer complications, healthcare providers are motivated to adopt these innovative techniques. The development of user-friendly robotic systems and improved laparoscopic tools further supports this trend, potentially leading to better patient outcomes. By investing in these advancements, medical facilities can attract a larger patient population seeking effective and less invasive solutions for managing uterine fibroids.

• Increasing Public Awareness in Uterine Fibroids

Increasing public awareness about uterine fibroids and the various treatment options available can significantly drive demand for myomectomy procedures. Educational campaigns aimed at both patients and healthcare professionals are crucial in enhancing understanding of this common condition and its symptoms. By providing information on the potential complications of untreated fibroids and the benefits of timely intervention, these initiatives can encourage more women to seek diagnosis and consider myomectomy as a viable treatment option. Moreover, equipping healthcare providers with the latest knowledge on fibroid management can lead to earlier referrals and improved patient outcomes. This heightened awareness creates a fertile ground for growth in the myomectomy market.

Restraints/Challenges

• Competition from Alternative Treatments

The presence of alternative therapies, such as medication and less invasive procedures such as uterine artery embolization, poses a significant challenge to the myomectomy market. Many patients are increasingly inclined to explore these options due to their non-invasive nature and perceived lower risk profiles. Medications can offer symptom relief without the need for surgery, while uterine artery embolization provides a less invasive way to treat fibroids with shorter recovery times. This trend may lead to a decline in the number of women opting for myomectomy, as they may prioritize these alternative treatments over traditional surgical interventions. Consequently, healthcare providers must navigate this competitive landscape to promote myomectomy effectively.

• High Costs of Treatment

The financial burden associated with myomectomy can be a considerable restraint on its market growth, as the costs encompass various factors, including surgery fees, hospitalization, anesthesia, and postoperative care. For many patients, particularly those without comprehensive insurance coverage, these expenses can be overwhelming and may deter them from seeking necessary treatment. The high out-of-pocket costs may lead some women to delay surgery or opt for alternative treatments that are perceived as more affordable. This financial barrier restricts access to myomectomy, resulting in unmet medical needs and contributing to a lower rate of procedure adoption among eligible patients.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Myomectomy Market Scope

The market is segmented on the basis of type, product, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Robotic Myomectomy
• Abdominal Myomectomy
• Hysteroscopic Myomectomy
• Laparoscopic Myomectomy

Product

• Laparoscopic Power Morcellators
• Harmonic Scalpel
• Laparoscopic Sealer
• Others

End User

• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Medical Device Companies

Myomectomy Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, product, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

The North America region is at the forefront of the myomectomy market, driven by a growing patient population affected by uterine fibroids and robust medical reimbursement options. The accessibility of comprehensive healthcare coverage enables more women to seek myomectomy as an effective treatment choice. Additionally, advancements in surgical techniques and increased awareness of women's health issues further bolster the demand for myomectomy procedures in this region.

The Asia-Pacific region is poised for substantial growth in the myomectomy market from 2024 to 2031, driven by a rising number of women experiencing uterine fibroids. Increased awareness about the diagnosis and treatment options available for fibroids is fostering greater demand for surgical interventions. Additionally, the rapid modernization of healthcare infrastructure in many Asia-Pacific countries is enhancing access to advanced medical technologies and services, further supporting market expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Myomectomy Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Myomectomy Market Leaders Operating in the Market Are:

• Boston Scientific Corporation (U.S.)
• CooperSurgical Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Karl Storz SE (Germany)
• Richard Wolf GmbH (Germany)
• AbbVie Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Medtronic (Ireland)
• Stryker (U.S.)
• CONMED Corporation (U.S.)
• Hologic, Inc. (U.S.)
• B. Braun SE (Germany)

Latest Developments in Myomectomy Market

• In October 2021, Gynesonics, a company dedicated to developing minimally invasive solutions for symptomatic uterine fibroids, announced that Dr. John Thoppil became the first physician in Texas to provide its Sonata treatment. This innovative procedure is now available to women with symptomatic uterine fibroids at his River Place OB/GYN facility in Austin, Texas. By offering this office-based solution, Dr. Thoppil aims to enhance patient care and provide an effective alternative for managing uterine fibroids
• In September 2021, Gynesonics, a company specializing in minimally invasive solutions for symptomatic uterine fibroids, announced that the Food and Drug Administration (FDA) granted clearance for the Sonata® System 2.2. This updated system introduces significant new benefits for healthcare facilities, physicians, and patients alike. The approval underscores Gynesonics' commitment to advancing treatment options for women suffering from uterine fibroids, enhancing both the efficacy and accessibility of care
• 2021년 10월, Hologic, Inc.는 최첨단 에너지 혈관 봉합 수술 장치로 유명한 미국의 민간 기업인 Bolder Surgical을 인수했습니다. 이 인수는 Hologic의 수술 포트폴리오를 확대했을 뿐만 아니라 의료 시장에서의 경쟁력을 강화했습니다. Bolder Surgical의 혁신적인 기술을 통합함으로써 Hologic은 제공 서비스를 강화하고 환자의 수술 결과를 개선하는 것을 목표로 합니다.
• 2021년 8월, 여성 건강 분야의 선도적인 글로벌 기업인 Hologic, Inc.는 미국에서 두 번째로 큰 건강 보험인 Anthem Blue Cross Blue Shield가 의료 정책을 개정하여 고주파 절제술(LAP-RFA)에 대한 적용 범위를 포함했다고 발표했습니다. 이 업데이트는 자궁 근종을 겪는 여성을 위한 Acessa 시술(CPT 코드 58674)을 구체적으로 포함합니다. 적용 범위를 확대하기로 한 결정은 이 흔한 질환에 대한 효과적인 치료 옵션에 대한 필요성이 점차 인식되고 있음을 반영하며, 궁극적으로 영향을 받는 환자의 치료 접근성을 개선합니다.
• 2020년 8월, Hologic Inc.는 자궁 근종에 대한 최소 침습적 치료법에 중점을 둔 것으로 유명한 민간 기업인 Acessa Health Inc.를 인수했습니다. 이 전략적 인수를 통해 Hologic은 근종 치료 시장에서 제품 제공을 강화하여 더 광범위한 혁신적 솔루션을 제공할 수 있게 되었습니다. Acessa Health의 전문성과 기술을 통합하여 Hologic은 근종으로 고통받는 여성의 환자 치료를 개선하고 치료 결과를 개선하는 것을 목표로 합니다.

SKU-63640